{"id":191025,"date":"2026-08-07T14:11:12","date_gmt":"2026-08-07T08:41:12","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=191025"},"modified":"2026-08-07T14:11:13","modified_gmt":"2026-08-07T08:41:13","slug":"emcure-pharmaceuticals-share-price-target-2027-2028-2030","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/","title":{"rendered":"Emcure Pharmaceuticals Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>CMP Rs 1790.3. FY26 EPS Rs 48.8; 15% annual growth. Target 2027: Rs 1,795 (+0%). Target 2028: Rs 2,060. Target 2030: Rs 2,730 (+52%).<\/em><\/p>\n<p>Emcure Pharmaceuticals at Rs 1,790.3 is a company with a familiar face: Executive Director Namita Thapar appears regularly on Shark Tank India, giving Emcure retail brand recognition that most pharma companies lack. But the Emcure Pharmaceuticals share price target of Rs 1,795 for 2027, rising to Rs 2,730 by 2030, rests on a different foundation: a complex generics and specialty pharma portfolio spanning gynaecology, oncology, and cardiovascular therapy with significant Europe and North America revenue.<\/p>\n<p>The Emcure Pharmaceuticals share price target of Rs 1,795 for 2027, rising to Rs 2,730 by 2030, reflects 15% annual earnings growth with a forward multiple consistent with Pharma peers. This article covers the Emcure Pharmaceuticals share price target 2027, 2028, and 2030 based on FY26 financials and analyst estimates as of August 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=emcure-pharmaceuticals-tgt\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Emcure_Pharmaceuticals_Company_Overview\" title=\"Emcure Pharmaceuticals Company Overview\">Emcure Pharmaceuticals Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Why_Is_the_Emcure_Pharmaceuticals_Share_Price_Target_Set_at_Rs_1795_for_2027\" title=\"Why Is the Emcure Pharmaceuticals Share Price Target Set at Rs 1,795 for 2027\">Why Is the Emcure Pharmaceuticals Share Price Target Set at Rs 1,795 for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Complex_Generics_in_Gynaecology_and_Oncology_Drive_International_Revenue\" title=\"Complex Generics in Gynaecology and Oncology Drive International Revenue\">Complex Generics in Gynaecology and Oncology Drive International Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Specialty_Pharma_Pipeline_Provides_Earnings_Upside_Beyond_Base_Formulations\" title=\"Specialty Pharma Pipeline Provides Earnings Upside Beyond Base Formulations\">Specialty Pharma Pipeline Provides Earnings Upside Beyond Base Formulations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Bain_Capital_Residual_Stake_Is_a_Known_and_Declining_Supply_Overhang\" title=\"Bain Capital Residual Stake Is a Known and Declining Supply Overhang\">Bain Capital Residual Stake Is a Known and Declining Supply Overhang<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#European_and_North_American_Expansion_Is_the_Long-Term_Earnings_Driver\" title=\"European and North American Expansion Is the Long-Term Earnings Driver\">European and North American Expansion Is the Long-Term Earnings Driver<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Domestic_Branded_Generics_Brand_Recognition_Supported_by_Promoter_Visibility\" title=\"Domestic Branded Generics Brand Recognition Supported by Promoter Visibility\">Domestic Branded Generics Brand Recognition Supported by Promoter Visibility<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Emcure_Pharmaceuticals_Share_Price_Targets_2027_2028_and_2030\" title=\"Emcure Pharmaceuticals Share Price Targets 2027, 2028 and 2030\">Emcure Pharmaceuticals Share Price Targets 2027, 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Emcure_Pharmaceuticals_Share_Price_Target_2027_Rs_1795\" title=\"Emcure Pharmaceuticals Share Price Target 2027: Rs 1,795\">Emcure Pharmaceuticals Share Price Target 2027: Rs 1,795<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Emcure_Pharmaceuticals_Share_Price_Target_2028_Rs_2060\" title=\"Emcure Pharmaceuticals Share Price Target 2028: Rs 2,060\">Emcure Pharmaceuticals Share Price Target 2028: Rs 2,060<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Emcure_Pharmaceuticals_Share_Price_Target_2030_Rs_2730\" title=\"Emcure Pharmaceuticals Share Price Target 2030: Rs 2,730\">Emcure Pharmaceuticals Share Price Target 2030: Rs 2,730<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Bull_Case_and_Bear_Case_for_the_Emcure_Pharmaceuticals_Share_Price_Target_2030\" title=\"Bull Case and Bear Case for the Emcure Pharmaceuticals Share Price Target 2030\">Bull Case and Bear Case for the Emcure Pharmaceuticals Share Price Target 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Bull_Case_Rs_3494\" title=\"Bull Case: Rs 3,494\">Bull Case: Rs 3,494<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Bear_Case_Rs_2075\" title=\"Bear Case: Rs 2,075\">Bear Case: Rs 2,075<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Key_Risks_to_the_Emcure_Pharmaceuticals_Share_Price_Target\" title=\"Key Risks to the Emcure Pharmaceuticals Share Price Target\">Key Risks to the Emcure Pharmaceuticals Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#USFDA_Inspection_and_Compliance_Risk\" title=\"USFDA Inspection and Compliance Risk\">USFDA Inspection and Compliance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Currency_Risk_on_Export_Revenue\" title=\"Currency Risk on Export Revenue\">Currency Risk on Export Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Pricing_Pressure_in_Regulated_Generic_Markets\" title=\"Pricing Pressure in Regulated Generic Markets\">Pricing Pressure in Regulated Generic Markets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Clinical_Trial_and_Pipeline_Risk\" title=\"Clinical Trial and Pipeline Risk\">Clinical Trial and Pipeline Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#How_to_Invest_in_Emcure_Pharmaceuticals\" title=\"How to Invest in Emcure Pharmaceuticals\">How to Invest in Emcure Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Frequently_Asked_Questions_on_Emcure_Pharmaceuticals_Share_Price_Target_2027_2028_and_2030\" title=\"Frequently Asked Questions on Emcure Pharmaceuticals Share Price Target 2027 2028 and 2030\">Frequently Asked Questions on Emcure Pharmaceuticals Share Price Target 2027 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_the_Emcure_Pharmaceuticals_share_price_target_for_2027\" title=\"What is the Emcure Pharmaceuticals share price target for 2027?\">What is the Emcure Pharmaceuticals share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_the_Emcure_Pharmaceuticals_share_price_target_for_2030\" title=\"What is the Emcure Pharmaceuticals share price target for 2030?\">What is the Emcure Pharmaceuticals share price target for 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#Is_Emcure_Pharmaceuticals_a_good_long-term_investment\" title=\"Is Emcure Pharmaceuticals a good long-term investment?\">Is Emcure Pharmaceuticals a good long-term investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#What_do_most_investors_miss_about_Emcure_Pharmaceuticals\" title=\"What do most investors miss about Emcure Pharmaceuticals?\">What do most investors miss about Emcure Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_the_bull_case_for_the_Emcure_Pharmaceuticals_share_price_target_2030\" title=\"What is the bull case for the Emcure Pharmaceuticals share price target 2030?\">What is the bull case for the Emcure Pharmaceuticals share price target 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#What_are_the_main_risks_to_the_Emcure_Pharmaceuticals_share_price_target\" title=\"What are the main risks to the Emcure Pharmaceuticals share price target?\">What are the main risks to the Emcure Pharmaceuticals share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_Emcure_Pharmaceuticalss_52-week_high_and_low_share_price\" title=\"What is Emcure Pharmaceuticals&#8217;s 52-week high and low share price?\">What is Emcure Pharmaceuticals&#8217;s 52-week high and low share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-share-price-target-2027-2028-2030\/#How_can_I_buy_Emcure_Pharmaceuticals_shares\" title=\"How can I buy Emcure Pharmaceuticals shares?\">How can I buy Emcure Pharmaceuticals shares?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Company_Overview\"><\/span><strong>Emcure Pharmaceuticals Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Metric<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Details<\/th>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">NSE Ticker<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\"><a href=\"https:\/\/univest.in\/stocks\/emcure\/emcure-pharmaceuticals-ltd-share-price-today\">EMCURE<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Sector<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Pharma<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">CMP (07 Aug 2026)<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1790.3<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">52-Week High<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,100<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">52-Week Low<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,250<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Market Cap<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 34,448 Cr<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">FY26 EPS<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 48.8 (15% annual growth)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Promoter Holding<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">57%<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">12M Consensus<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">\u20b91,720 (-4%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Emcure Pharmaceuticals Share Price Target 2027<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,795 (+0%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Emcure Pharmaceuticals Share Price Target 2028<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,060 (+15%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Emcure Pharmaceuticals Share Price Target 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,730 (+52%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 3,494<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,075<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"border-left: 4px solid #e67e22; background: #FEF9F0; padding: 10px 16px;\"><strong>What most investors miss:<\/strong> Bain Capital was a pre-IPO PE backer of Emcure, retaining a residual post-IPO stake that is a potential supply overhang. Executive Director Namita Thapar, of Shark Tank India fame, is a promoter shareholder whose public visibility is the brand, not the business model. The stock&#8217;s 2027 target of Rs 1,795 essentially represents flat earnings-to-valuation, with the compounding case playing out from 2028 to 2030 as the specialty pharma pipeline matures.<\/p>\n<p>FY26 EPS of \u20b948. 8 growing approximately15% a year, capitalised at approximately32x forward earnings; growth tapers to approximately12% further out. The share price targets of Rs 1,795 for 2027, Rs 2,060 for 2028, and Rs 2,730 for 2030 are derived from this earnings trajectory and peer multiples.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Emcure_Pharmaceuticals_Share_Price_Target_Set_at_Rs_1795_for_2027\"><\/span><strong>Why Is the Emcure Pharmaceuticals Share Price Target Set at Rs 1,795 for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Complex_Generics_in_Gynaecology_and_Oncology_Drive_International_Revenue\"><\/span><strong>Complex Generics in Gynaecology and Oncology Drive International Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the foundational driver of the Emcure Pharmaceuticals share price target of Rs 1,795 for 2027 and Rs 2,730 by 2030. FY26 EPS of \u20b948.8 growing approximately15% a year, capitalised at approximately32x forward earnings; growth tapers to approximately12% further out. Street consensus (1-yr) sits at \u20b91,720. The market will progressively price this as quarterly data confirms the trajectory.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Specialty_Pharma_Pipeline_Provides_Earnings_Upside_Beyond_Base_Formulations\"><\/span><strong>Specialty Pharma Pipeline Provides Earnings Upside Beyond Base Formulations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Investors analysing the Emcure Pharmaceuticals share price target should track this dimension quarterly, as it provides the clearest signal of whether the compounding thesis is on track. Evidence of sustained improvement in this area is the primary re-rating catalyst for the Emcure Pharmaceuticals share price target 2028 of Rs 1969.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bain_Capital_Residual_Stake_Is_a_Known_and_Declining_Supply_Overhang\"><\/span><strong>Bain Capital Residual Stake Is a Known and Declining Supply Overhang<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This structural factor is often underweighted in standard Emcure Pharmaceuticals share price target analyses, which focus on trailing earnings multiples rather than the competitive positioning embedded in the long-term franchise value. Its persistence through economic cycles is what differentiates the Emcure Pharmaceuticals share price target 2030 case from a short-term trading call.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"European_and_North_American_Expansion_Is_the_Long-Term_Earnings_Driver\"><\/span><strong>European and North American Expansion Is the Long-Term Earnings Driver<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For the Emcure Pharmaceuticals share price target of Rs 2,730 to materialise by 2030, this factor needs to remain intact and compound over 4 years. Quarterly updates on this metric provide the earliest warning signal of any deviation from the Emcure Pharmaceuticals share price target base case assumptions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_Branded_Generics_Brand_Recognition_Supported_by_Promoter_Visibility\"><\/span><strong>Domestic Branded Generics Brand Recognition Supported by Promoter Visibility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As India&#8217;s economy compounds through 2027 to 2030, this factor provides an additional secular tailwind that is layered on top of the Emcure Pharmaceuticals-specific earnings growth already embedded in the Rs 1,795 target for 2027 and the Rs 2,730 target for 2030.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Share_Price_Targets_2027_2028_and_2030\"><\/span><strong>Emcure Pharmaceuticals Share Price Targets 2027, 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Share_Price_Target_2027_Rs_1795\"><\/span><strong>Emcure Pharmaceuticals Share Price Target 2027: Rs 1,795<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Emcure Pharmaceuticals share price target 2027 is Rs 1,795, representing approximately 0 percent upside from CMP Rs 1790.3. FY26 EPS of \u20b948.8 growing approximately15% a year, capitalised at approximately32x forward earnings; growth tapers to approximately12% further out. Street consensus (1-yr) sits at \u20b91,720.. By 2027, the key catalyst for achieving this level is validation of the earnings trajectory through 2 consecutive quarters of on-target performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Share_Price_Target_2028_Rs_2060\"><\/span><strong>Emcure Pharmaceuticals Share Price Target 2028: Rs 2,060<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Emcure Pharmaceuticals share price target 2028 is Rs 2,060, implying approximately 15 percent upside from CMP. By 2028, Emcure Pharmaceuticals should have demonstrated through a full earnings cycle that the 15% growth assumption is sustainable, supporting a re-rating toward the Emcure Pharmaceuticals share price target 2028 level at a forward multiple consistent with sector peers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Share_Price_Target_2030_Rs_2730\"><\/span><strong>Emcure Pharmaceuticals Share Price Target 2030: Rs 2,730<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Emcure Pharmaceuticals share price target 2030 is Rs 2,730, implying approximately 52 percent upside from CMP and a 4-year CAGR of approximately 11% from current levels. By 2030, Emcure Pharmaceuticals should be a mature, well-understood franchise with a track record of consistent compounding that justifies the target multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_for_the_Emcure_Pharmaceuticals_Share_Price_Target_2030\"><\/span><strong>Bull Case and Bear Case for the Emcure Pharmaceuticals Share Price Target 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_3494\"><\/span><strong>Bull Case: Rs 3,494<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Emcure Pharmaceuticals share price target of Rs 3,494 by 2030: Rs 3,400 by 2030, requiring 18 percent EPS growth driven by successful launches in the US specialty market and Europe branded generics. Namita Thapar&#8217;s public profile accelerating domestic OTC product launches would add incremental revenue above the base case.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Rs_2075\"><\/span><strong>Bear Case: Rs 2,075<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bear case Emcure Pharmaceuticals share price target of Rs 2,075 by 2030: Rs 2,100 by 2030, if the US specialty market approvals take longer than expected, Bain Capital&#8217;s residual stake continues to weigh on sentiment, and domestic branded generics face pricing pressure from generic substitution policies.<\/p>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Scenario<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Target by 2030<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Return<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Key Assumption<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 3,494<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+95%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Upside scenario with favourable execution and sector conditions<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Base Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,730<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+52%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">15% EPS CAGR; peer-multiple sustained through FY31<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,075<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+16%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Downside scenario with adverse execution or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Emcure_Pharmaceuticals_Share_Price_Target\"><\/span><strong>Key Risks to the Emcure Pharmaceuticals Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"USFDA_Inspection_and_Compliance_Risk\"><\/span><strong>USFDA Inspection and Compliance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any USFDA warning letter or import alert on Emcure Pharmaceuticals&#8217;s manufacturing facilities would delay product launches and revenue recognition, directly reducing the earnings trajectory behind the Emcure Pharmaceuticals share price target. USFDA inspection history is the most important risk indicator to track.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Currency_Risk_on_Export_Revenue\"><\/span><strong>Currency Risk on Export Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Emcure Pharmaceuticals&#8217;s international revenue is primarily in US dollars and euros. Any significant INR appreciation against these currencies would reduce the INR value of reported revenues and EPS, compressing the Emcure Pharmaceuticals share price target earnings assumptions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Pricing_Pressure_in_Regulated_Generic_Markets\"><\/span><strong>Pricing Pressure in Regulated Generic Markets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the US and EU generic markets, pricing erosion from competition intensifies as multiple players receive approvals for the same molecule. Any acceleration in generic pricing erosion in Emcure Pharmaceuticals&#8217;s key export products would compress the Emcure Pharmaceuticals share price target revenue base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Clinical_Trial_and_Pipeline_Risk\"><\/span><strong>Clinical Trial and Pipeline Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any setback in Emcure Pharmaceuticals&#8217;s clinical trial results or regulatory approvals for pipeline products would delay the revenue ramp from specialty or novel products embedded in the Emcure Pharmaceuticals share price target 2028 and 2030 assumptions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Emcure_Pharmaceuticals\"><\/span><strong>How to Invest in Emcure Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use the Univest Screener to track Emcure Pharmaceuticals&#8217;s key financial metrics including EPS growth, margin trends, and analyst upgrades or downgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker EMCURE. Review the quarterly earnings data, the sector-specific risk indicators outlined in this article, and build a position size proportionate to your risk tolerance and investment horizon. Monitor each quarter for the key variables most likely to move the Emcure Pharmaceuticals share price target. Consult a SEBI-registered financial advisor before making any investment decision.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Track This Stock Live<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Emcure Pharmaceuticals share price target of Rs 1,795 for 2027, Rs 2,060 for 2028, and Rs 2,730 for 2030 reflects 15% annual earnings compounding and a forward multiple consistent with Pharma peers. The key drivers and risks are outlined above. Bain Capital was a pre-IPO PE backer of Emcure, retaining a residual post-IPO stake that is a potential supply overhang. Executive Director Namita Tha. For investors with a 3 to 4 year horizon and a tolerance for Pharma-specific risk, the current CMP of Rs 1790.3 offers a starting point for building a position aligned to the Emcure Pharmaceuticals share price target 2030 thesis. Always verify data at NSE and BSE before investing.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-portfolio\/id1479183301\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=in.univest.app\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Emcure Pharmaceuticals share price live and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Emcure_Pharmaceuticals_Share_Price_Target_2027_2028_and_2030\"><\/span><strong>Frequently Asked Questions on Emcure Pharmaceuticals Share Price Target 2027 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Emcure_Pharmaceuticals_share_price_target_for_2027\"><\/span><strong>What is the Emcure Pharmaceuticals share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Emcure Pharmaceuticals share price target for 2027 is Rs 1,795, representing approximately 0 percent upside from CMP Rs 1790.3 as of August 2026. Please verify all data with the official NSE website before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Emcure_Pharmaceuticals_share_price_target_for_2030\"><\/span><strong>What is the Emcure Pharmaceuticals share price target for 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Emcure Pharmaceuticals share price target for 2030 is Rs 2,730, implying approximately 52 percent upside from CMP Rs 1790.3. This is based on analyst estimates and is not a guaranteed return. Always verify current data at NSE India before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Emcure_Pharmaceuticals_a_good_long-term_investment\"><\/span><strong>Is Emcure Pharmaceuticals a good long-term investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Emcure Pharmaceuticals has a defined analyst consensus that projects earnings compounding through FY31 based on sector-specific growth drivers outlined in this article. Whether it suits your portfolio depends on your risk appetite, investment horizon, and existing allocation. Consult a SEBI-registered financial advisor for personalised guidance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_do_most_investors_miss_about_Emcure_Pharmaceuticals\"><\/span><strong>What do most investors miss about Emcure Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bain Capital was a pre-IPO PE backer (invested 2013) and retains a residual post-IPO stake creating a potential supply overhang; Executive Director Namita Thapar (Shark Tank India judge) is promoter Satish Mehta&#8217;s daughter, i.e. concentrated family management. Strong hidden franchise in HIV antiretr<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_bull_case_for_the_Emcure_Pharmaceuticals_share_price_target_2030\"><\/span><strong>What is the bull case for the Emcure Pharmaceuticals share price target 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case Emcure Pharmaceuticals share price target for 2030 is Rs 3,494. This requires better-than-base-case execution on the key growth drivers specific to Emcure Pharmaceuticals&#8217;s sector, as described in this article. These are analyst projections, not guaranteed returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Emcure_Pharmaceuticals_share_price_target\"><\/span><strong>What are the main risks to the Emcure Pharmaceuticals share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key risks to the Emcure Pharmaceuticals share price target include sector-specific headwinds such as credit cycles (for financial companies), regulatory changes, competitive pressure, and macroeconomic slowdown. Please review the risks section of this article for a full breakdown of the four most material risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Emcure_Pharmaceuticalss_52-week_high_and_low_share_price\"><\/span><strong>What is Emcure Pharmaceuticals&#8217;s 52-week high and low share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of August 2026, Emcure Pharmaceuticals&#8217;s 52-week high is approximately Rs 2,100 and the 52-week low is approximately Rs 1,250. The CMP of Rs 1790.3 sits between these levels. Always verify the latest 52-week data at NSE India or BSE before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_buy_Emcure_Pharmaceuticals_shares\"><\/span><strong>How can I buy Emcure Pharmaceuticals shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy Emcure Pharmaceuticals shares through any SEBI-registered broker by searching for the NSE ticker EMCURE. Before investing, review the fundamentals outlined in this article and consult a SEBI-registered financial advisor for guidance aligned to your specific financial goals.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Emcure Pharmaceuticals share price target 2027 is Rs 1,795 (+0%), 2028 is Rs 2,060, and 2030 is Rs 2,730 (+52%). Pharma stock. Full long term analyst forecast.<\/p>\n","protected":false},"author":36,"featured_media":191024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-191025","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["191024"],"_edit_lock":["1786092076:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Emcure Pharmaceuticals Share Price Target 2027 2028 and 2030"],"rank_math_description":["Emcure Pharmaceuticals share price target 2027 is Rs 1,795 (+0%), 2028 is Rs 2,060, and 2030 is Rs 2,730 (+52%). Pharma stock. Full long term analyst forecast."],"rank_math_focus_keyword":["Emcure Pharmaceuticals share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35035"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/emcure-pharmaceuticals-share-price-target-2027-2028-2030-1.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/191025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=191025"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/191025\/revisions"}],"predecessor-version":[{"id":191035,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/191025\/revisions\/191035"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/191024"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=191025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=191025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=191025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}